Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL

Primary mediastinal large B-cell lymphoma (PMBL), a distinct mature B-cell lymphoma, expresses CD20 and has recently been successfully treated with the combination of a type I anti-CD20 monoclonal antibody, rituximab, with multiple combination chemotherapy regimens. Obinutuzumab is a glycoengineered...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Yaya, Awasthi, Aradhana, Lee, Sanghoon, Edani, Dina, Yin, Changhong, Hochberg, Jessica, Shah, Tishi, Chung, Tae-Hoon, Ayello, Janet, van de Ven, Carmella, Klein, Christian, Lee, Dean, Cairo, Mitchell S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429176/
https://www.ncbi.nlm.nih.gov/pubmed/32850008
http://dx.doi.org/10.18632/oncotarget.27691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429176/
https://www.ncbi.nlm.nih.gov/pubmed/32850008
http://dx.doi.org/10.18632/oncotarget.27691

Ejemplares similares